Cicco-Ostarine MK-2866 12.5mg

Cicco-ostarine MK-2866 12.5mgCicco-Ostarine MK-2866 12.5mg

SELECTIVE ANDROGEN RECEPTOR MODULATOR – SARM

DISCLAIMER – IMPORTANT:
Selective Androgen Receptor Modulators (SARMs) should NOT BE USED by children, teenagers and pregnant or nursing women. SARMs are meant for men and women over 21 years of age who are fully developed adults.

Although SARMs are non-steroids, they are still performance enhancers and banned by certain organisations governing professional athletes. It’s your responsibility to perform due-diligence to ensure compliance.

WADA’s (World Anti—Doping Agency) prohibited list states that SARMs have been prohibited by the World Anti—Doping Agency (WADA) since 2008. SARMs have the potential to be misused for performance enhancement in sport due to their anabolic properties as well as the ability to stimulate androgen receptors in muscle and bone. They are currently prohibited in category of “other anabolic agents” under section Sl.2 of the WADA Prohibited List. Some examples of SARMs are Ostarine and Andarine.

At the moment, SARMs are not classified as a scheduled drug, neither are they classified as a food supplement. SARMs are not illegal but they are seen as possible new drug candidates currently categorised for research purposes only.

PHARMACOLOGICAL CLASSIFICATION:
Cicco-Ostarine MK-2866 12.5mg is an oral Selective Androgen Receptor Modulator (SARM) research drug currently noted as a possible new drug candidate.

GENERAL PHARMACOLOGICAL ACTION:
Non-steroidal SARMs act on specific androgen receptors in a number of key tissues found all over the human body. Some androgen receptors worth mentioning are found in the prostate, seminal vesicle, male and female genitalia, skin, testis, ovary, cartilage, sebaceous glands, hair follicles, sweat glands, cardiac muscle, smooth muscle, gastrointestinal vesicular cells, thyroid follicular cells, adrenal cortex, liver, pineal, and brain.

Currently, Ciccone Pharma SARMs are being administered as a research drug to treat hypogonadism by increasing levels of the natural Androgen Receptor (AR) ligands testosterone (T) and DHT. Male hypogonadism is a condition where not enough testosterone is being produced. This is a condition that you can be born with, or it could develop as a result of an injury, old age or an infection. The effects of hypogonadism are muscle mass loss, depression, increase in body fat and a low libido. Administering SARMs will reverse the effects of hypogonadism, but unlike other exogenous androgens, SARMs will not affect the prostate.

SARMs act as an antagonist to the androgenic organs like the prostate and bind directly to the receptors and are an agonist in anabolic tissues like muscle and bone.

The key benefits of SARMs are an increase in muscle mass, decreased fat mass and increased bone mass.

Phase I clinical trials of Ciccone Pharma SARMs measured an increase of l.5 kg of muscle mass in a 4-6 week trial period with no significant increase in body fat. These trials were not done on healthy athletes who follow an eating regime that support muscle gain. The trials were done on people with muscle-wasting illnesses.

SARMs also activate AMPK, a mechanism involved in fat oxidation and lipolysis. Testosterone-derived compounds also increase muscle mass and decrease fat mass, but unlike these compounds, SARMs do not significantly suppress LH and FSH levels unless exceptionally high doses (3-4x the median effective dose) are administered. This further supports the notion that SARMs may be safer long-term than testosterone-derived steroidal compounds.

Androgens appear to increase periosteal bone formation in cortical bone whereas oestrogen compounds decrease this formation. Androgens help to build the dense and compact outer layer of the bone which help support the skeleton, protect organs, store calcium, and provide levers for movement. Increase in bone formation and decreasing of bone turnover suggests SARMs as a treatment for patients developing or already diagnosed with osteoporosis.

SPECIFIC PHARMACOLOGICAL ACTION:

Cicco-Ostarine MK-2866 12.5mg increases lean muscle mass, increases endurance and increases strength. It promotes healing of bone and tendon related injuries.

Cicco-Ostarine MK-2866 12.5mg is anabolic at doses as low as} mg per day.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Very few side effects have been noted with Ciccone Pharma SARMs and the suppression of the HPTA (Hypothalamic-Pituitary-Testicular Axis). The only side effect documented is when recommended doses are excessively exceeded and the substance has been abused. Maximum doses are being stipulated on the back of every Ciccone Pharma SARM.